<DOC>
	<DOCNO>NCT03023852</DOCNO>
	<brief_summary>The purpose study assess rate extent absorption JNJ63623872 follow administration single oral dose 2*300 milligram ( mg ) give 2 concept single agent tablet formulation compare administration 2*300 mg JNJ63623872 reference tablet , fast condition healthy adult participant assess rate extent absorption JNJ63623872 oseltamivir follow administration single oral dose 2*300 mg/37.5 mg JNJ63623872/ oseltamivir give concept fix dose combination ( FDC ) tablet formulation compare coadministration 2*300 mg JNJ63623872 tablet ( reference formulation ) 1*75 mg oseltamivir capsule , fast condition healthy adult participant .</brief_summary>
	<brief_title>A Study Assess Relative Oral Bioavailability Single Dose JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet Single Agent Concept Formulations JNJ-63623872 Compared Their Respective Reference Formulation Healthy Adult Participants</brief_title>
	<detailed_description />
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>A female participant must negative serum betahuman chorionic gonadotropin pregnancy test screen Day 1 treatment period Contraceptive use men woman consistent local regulation regard use contraceptive method participant participate clinical study A female participant must agree donate egg ( ovum , oocytes ) purpose assist reproduction study least 90 day receive last dose study drug Participant must body mass index ( BMI ) , weight kilogram per height square meter square [ kg ] /height^2 [ ] ^2 ) 18.0 30.0 kilogram per meter square ( kg/m^2 ) ( extremes include ) screening . The minimum weight 50.0 kilogram ( kg ) Participant must blood pressure ( supine least 5 minute rest ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic screen Participant must nonsmoker least 3 month prior screen Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , diabetes mellitus , hepatic renal insufficiency , gastrointestinal disease , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result Participant past history heart arrhythmia ( extrasystoli , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( eg , hypokalemia , family history long QT Syndrome ) Participant history clinically significant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria Participant know allergy heparin history heparin induce thrombocytopenia Participant donate blood blood product substantial loss blood ( 500 milliliter ( mL ) within 3 month first administration study drug intention donate blood blood product study A woman pregnant , breastfeeding , plan become pregnant study , woman childbearing potential unwilling use acceptable method contraception Participant history hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) antibody positive , clinically active liver disease , test positive HBsAg antiHCV screen Participant history human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection , test positive HIV1 2 screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>